1. Home
  2. CHSCL vs BBIO Comparison

CHSCL vs BBIO Comparison

Compare CHSCL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHSCL
  • BBIO
  • Stock Information
  • Founded
  • CHSCL N/A
  • BBIO 2015
  • Country
  • CHSCL United States
  • BBIO United States
  • Employees
  • CHSCL N/A
  • BBIO N/A
  • Industry
  • CHSCL Farming/Seeds/Milling
  • BBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHSCL Industrials
  • BBIO Health Care
  • Exchange
  • CHSCL Nasdaq
  • BBIO Nasdaq
  • Market Cap
  • CHSCL N/A
  • BBIO 6.7B
  • IPO Year
  • CHSCL N/A
  • BBIO 2019
  • Fundamental
  • Price
  • CHSCL $25.61
  • BBIO $34.17
  • Analyst Decision
  • CHSCL
  • BBIO Strong Buy
  • Analyst Count
  • CHSCL 0
  • BBIO 12
  • Target Price
  • CHSCL N/A
  • BBIO $57.09
  • AVG Volume (30 Days)
  • CHSCL N/A
  • BBIO 3.1M
  • Earning Date
  • CHSCL N/A
  • BBIO 04-29-2025
  • Dividend Yield
  • CHSCL N/A
  • BBIO N/A
  • EPS Growth
  • CHSCL N/A
  • BBIO N/A
  • EPS
  • CHSCL N/A
  • BBIO N/A
  • Revenue
  • CHSCL N/A
  • BBIO $127,415,000.00
  • Revenue This Year
  • CHSCL N/A
  • BBIO $13.67
  • Revenue Next Year
  • CHSCL N/A
  • BBIO $118.02
  • P/E Ratio
  • CHSCL N/A
  • BBIO N/A
  • Revenue Growth
  • CHSCL N/A
  • BBIO N/A
  • 52 Week Low
  • CHSCL N/A
  • BBIO $21.62
  • 52 Week High
  • CHSCL N/A
  • BBIO $39.47
  • Technical
  • Relative Strength Index (RSI)
  • CHSCL 54.83
  • BBIO 44.19
  • Support Level
  • CHSCL $25.50
  • BBIO $33.92
  • Resistance Level
  • CHSCL $25.73
  • BBIO $39.16
  • Average True Range (ATR)
  • CHSCL 0.11
  • BBIO 1.50
  • MACD
  • CHSCL 0.03
  • BBIO -0.24
  • Stochastic Oscillator
  • CHSCL 81.98
  • BBIO 10.35

About CHSCL CHS Inc Class B Cumulative Redeemable Preferred Stock Series 4

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: